Upadacitinib and abrocitinib, both JAK1 inhibitors, have also shown promising short-term efficacy among approved systemic therapies, highlighting their potential role in managing the complex inflammatory pathways involved in AD [31]. Here, JAK1 is linked to Alzheimer disease.